GLP-1 Hemorrhoids: Why They Happen, What’s Serious, and What Actually Helps

By the Weight Loss Provider Guide Editorial Team · Last verified: July 18, 2026 · Next check: October 17, 2026

This page contains affiliate links. If you use them we may earn a commission, at no cost to you. No provider paid for placement, and no provider is recommended based on symptoms described here. This is general education, not medical advice.

You went to the bathroom, and there was blood. Or a lump showed up that wasn’t there last week. And somewhere in the back of your mind: is this the shot?

Here’s the honest answer. Hemorrhoid symptoms can show up or get worse while you’re on a GLP-1 — but there’s no established rate for how often that happens, and no label claims the drug attacks the veins directly. The documented pathway is indirect: constipation, hard stool, straining, frequent loose stools, and long sits on the toilet all trigger or aggravate hemorrhoids, and GLP-1 medications reliably cause the bowel changes that lead there.

So the lever is the stool, not the drug. That’s good news, because the stool is something you can change this week.

We pulled the current FDA prescribing information for the major GLP-1 and dual GIP/GLP-1 products and searched each one for the word hemorrhoids. Among the labels in our index, exactly one names it. The rest don’t mention it anywhere.

Most sites read that as proof one drug is rougher on your backside. That read doesn’t survive contact with the trial data. When tirzepatide and semaglutide were studied side by side under a single protocol, constipation came out at 27.0% and 28.5% — a gap of one and a half points. Compare the two labels on their own and you’d think the gap was 24% versus 11%. Same two drugs. Completely different picture depending on which numbers you use.

When is rectal bleeding on a GLP-1 an emergency?

Answer in brief

Rectal bleeding requires emergency evaluation when it is heavy or continuous, when the stool is black or tarry, when blood is mixed throughout the stool, or when it occurs alongside severe abdominal pain, fever, fainting, confusion, or a rapid heart rate. A small amount of bright red blood on the paper without those features is the most commonly reported pattern and is usually not an emergency, but color and volume alone do not identify the source, and new bleeding should be evaluated by a clinician.

How to use this table: This is our own educational framework for sorting urgency — not a validated clinical triage tool, and not a diagnosis. It combines the emergency bleeding signs published by NIDDK with the bowel effects that appear on GLP-1 labels.

The WLPG Anorectal Triage Framework (v1.0)

What actually causes GLP-1 hemorrhoids?

Answer in brief

GLP-1 medications are associated with hemorrhoid symptoms mainly through changes in bowel habits rather than a direct effect on hemorrhoidal tissue. Constipation, hard stool, and straining increase pressure on the vascular cushions in the anal canal, while frequent loose stools cause repeated wiping and moisture that irritate the same tissue. Diarrhea is reported more frequently than constipation on several GLP-1 products.

Hemorrhoids aren’t something you catch. Everyone has hemorrhoidal tissue — cushions of blood vessels in the anal canal that help you stay continent. They’re supposed to be there. They become a problem when pressure or friction makes them swell, bleed, or slip out of position.

ASCRS names constipation, straining, prolonged toilet sitting, and frequent bowel movements as contributors to symptomatic hemorrhoids (ASCRS, 2024). GLP-1 medications produce all four.

Route 1: hard stool and straining

Constipation is a documented adverse reaction across this drug class. In the adult Wegovy weight-reduction trials it was reported by 24% of patients versus 11% on placebo (Wegovy label, §6.1). Reduced food intake, nausea, or not drinking enough can all contribute. Less bulk, less water, less frequent urge — and what comes out is smaller, harder, and takes real effort. That effort is the problem. Straining raises pressure in the anal canal directly.

One caveat worth stating: GLP-1 medications delay gastric emptying — how fast food leaves your stomach. That’s a different process from how fast stool moves through your colon. What’s documented is simpler and enough: these medicines cause constipation, and hard stool plus straining aggravates hemorrhoids.

Route 2: diarrhea and friction

On several GLP-1 products, diarrhea is reported more often than constipation — not less:

• Wegovy 2.4 mg: diarrhea 30% vs. constipation 24% (label)
• Zepbound 15 mg arm: diarrhea 23% vs. constipation 11% (label)
• Ozempic 1 mg: diarrhea 8.8% vs. constipation 3.1% (label)

Frequent loose stools mean more trips, more urgency, more wiping, more moisture, more toilet time. That combination irritates and inflames the same tissue that straining does. Check which one you actually have before you treat it. That single step will save more people on this page than anything else.

Route 3: toilet time

Prolonged toilet sitting is associated with symptomatic hemorrhoids, and both ASCRS and the American Gastroenterological Association advise limiting time on the toilet and avoiding straining (AGA, ASCRS). If nothing is happening, get up and come back when the urge returns.

The escalation connection

The current Wegovy label says the additional gastrointestinal reactions it lists — the group that includes hemorrhoids — were most frequently reported during dosage escalation (Wegovy label, §6.1). Zepbound’s label makes a structurally similar point: the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time (Zepbound label, §6.1).

The period after a dose increase is when your bowels are most likely to change. Which makes it the period to pay attention, rather than the period to hope for the best. Most people find this out backwards: they increase, they get a hard stool, they strain, and now they’ve got a problem to solve instead of one they watched for.

Which GLP-1 labels name hemorrhoids?

Answer in brief

Among the FDA-approved GLP-1 and dual GIP/GLP-1 products indexed on this page, the adult Wegovy injection adverse-reaction text is the only one that names hemorrhoids, and it provides no hemorrhoid percentage. The labels for Zepbound, Ozempic, Mounjaro, Saxenda, and Foundayo do not name hemorrhoids, though all report constipation and diarrhea. A label that does not name hemorrhoids is not evidence that the medication cannot contribute to them.

WLPG GLP-1 Hemorrhoid Label Index — Version 1.0

Sources: Wegovy · Zepbound · Ozempic · Mounjaro · Saxenda

Four things this table shows that get lost everywhere else

1. The hemorrhoid mention is specific — to adults, and to the injection. The label’s wording names Wegovy injection-treated adult patients. The pediatric list in the same label includes constipation but not hemorrhoids. That precision gets flattened into “Wegovy causes hemorrhoids.”
2. No label gives a hemorrhoid percentage. Not one. Wegovy names hemorrhoids in a group of other GI reactions without attaching a number. If you see a site claiming “X% of Wegovy users get hemorrhoids,” that number did not come from the label.
3. “Not on the label” doesn’t mean “can’t happen.” Absence from a label tells you about the trial’s data collection, not about your anatomy.
4. Don’t confuse hemorrhoids with hemorrhagic. Several GLP-1 labels mention “hemorrhagic or necrotizing pancreatitis” in postmarketing sections. That’s a serious pancreas complication with nothing to do with hemorrhoids. Different words, different organs.

Is one GLP-1 safer than another for hemorrhoids?

Answer in brief

Adverse-event percentages from different drug labels cannot be compared directly, because the underlying trials enrolled different populations under different conditions. In SURMOUNT-5, where separate randomized groups received tirzepatide (n=374) or semaglutide (n=376) under a single protocol, constipation was reported by 27.0% and 28.5% respectively. That trial did not measure hemorrhoid incidence, and no published evidence establishes which GLP-1 carries a lower hemorrhoid risk.

Why the label percentages can’t be stacked against each other

Every label carries a version of the same warning: adverse-event rates from one drug’s trials cannot be directly compared to another’s, because the conditions differed. Look at Ozempic and Wegovy: same molecule. Semaglutide, both.

• Ozempic 1 mg: constipation 3.1%
• Wegovy 2.4 mg: constipation 24%

Roughly eight times the rate, same active drug. The dose differs, and one trial enrolled adults with type 2 diabetes while the other enrolled adults treated for obesity, over different durations.

The one comparison where that objection goes away

There’s exactly one place to look where the design objection doesn’t apply: a trial that gave both drugs to comparable participants at the same time under the same protocol. SURMOUNT-5 did that. Participants were randomized into separate groups — 374 received tirzepatide, 376 received semaglutide, under one set of rules.

Source: Lilly, Zepbound clinical data

Constipation: 1.5 percentage points apart. Diarrhea: one-tenth of a point. Put that next to the labels, where the same two drugs look like 24% and 11%. The gap disappears when they’re studied together.

One pattern worth knowing about the Zepbound arms

Read the Zepbound row left to right across the dose arms:

• Constipation: 17% → 14% → 11% across the 5, 10, and 15 mg arms.
• Diarrhea: 19% → 21% → 23% across the same arms.

One goes down as the dose goes up. The other goes up. They cross. At 15 mg, diarrhea (23%) is reported roughly twice as often as constipation (11%). If you’re at a higher tirzepatide dose, loose stool is the more commonly reported problem — which matters because the standard advice (more fiber, stool softener, more water) is built for the opposite problem. Find out which problem you have before you treat it.

Hemorrhoid, fissure, or something else? How to tell the difference.

Answer in brief

Internal hemorrhoids characteristically cause bright red bleeding with little or no pain. An anal fissure — a small tear in the lining of the anal canal — characteristically causes sharp, tearing pain during and after a bowel movement, often with a thin streak of blood. A sudden, firm, very painful lump at the anal opening fits a thrombosed external hemorrhoid. These patterns overlap, and distinguishing them reliably requires examination.

The tell is pain. Not the blood — the pain.

Our limitation, plainly: a webpage cannot identify the source of rectal bleeding with certainty. An examination is often needed. What we can do is help you tell “this can wait for Tuesday” from “this needs attention today,” and help you describe it accurately when you get there.

About the blood: why “it’s probably just the medication” is a sentence to be careful with

Answer in brief

Rectal bleeding is the strongest of four red-flag signs associated with early-onset colorectal cancer, with an odds ratio of 5.13 in a study of 5,075 cases published in the Journal of the National Cancer Institute. Odds ratios describe relative associations across a population and do not represent the probability that any individual with rectal bleeding has cancer. Most rectal bleeding has causes other than cancer, but new bleeding warrants clinical evaluation.

Read this calmly. We’re not telling you that you have cancer. Most rectal bleeding turns out to have a cause other than cancer, and hemorrhoids are far more common than anything serious. What we’re describing is a blind spot that applies specifically to people on GLP-1 medications.

The four red flags

In 2023, researchers published a study in the Journal of the National Cancer Institute examining 5,075 cases of colorectal cancer in adults under 50, matched against controls from 113 million insured adults, looking for signs that appeared months or years before diagnosis. Four stood out:

Count mattered too: one sign was associated with 1.94× the odds, two with 3.59×, three or more with 6.52× (JNCI, 2023).

Now look at that list as someone on a GLP-1

Three of those four signs are things your medication can produce on its own:

• Diarrhea — on the label. 30% for Wegovy, 23% in the Zepbound 15 mg arm.
• Abdominal pain — on the label for every product in our index.
• Rectal bleeding — well, you’ve got hemorrhoids. So that’s explained too.

The blind spot: for a person on a GLP-1, there’s a ready, reasonable, medically plausible explanation available for nearly every one of these signals. And that explanation is usually correct. That’s exactly what makes it worth naming — a plausible medication explanation can quietly delay evaluation if new bleeding gets dismissed automatically.

To be clear about what this is: that’s our concern based on symptom overlap. The colorectal cancer studies cited here did not test whether GLP-1 users experience diagnostic delay.

Why this matters more under 50

Routine screening for average-risk adults now begins at 45. But roughly half of early-onset colorectal cancers are diagnosed before 45 — below that threshold. A 2024 meta-analysis in JAMA Network Open pooling 81 studies and nearly 25 million patients under 50 found that about 45% of early-onset colorectal cancers presented with rectal bleeding (JAMA Network Open, 2024).

If you take a blood thinner

If you’re on warfarin, apixaban, rivaroxaban, clopidogrel, or daily aspirin, bleeding from a hemorrhoid can be heavier and slower to stop. Two rules:

• New bleeding means contacting the prescribing clinician promptly — not waiting to see how the week goes. Heavy or ongoing bleeding, dizziness, fainting, or the shock signs are urgent.
• Do not stop the blood thinner on your own. Not for a day. That decision belongs to whoever prescribed it, and stopping can carry considerably more risk than the bleeding.

“But I go every day.” Why it happens anyway.

Answer in brief

Bowel movement frequency does not indicate stool consistency, straining effort, or time spent on the toilet, each of which contributes independently to hemorrhoid symptoms. A daily bowel movement can still be hard, difficult to pass, or incompletely emptied.

You can be regular and still be doing damage. Frequency is the wrong measurement.

• Consistency. A daily bowel movement made of hard, dry pellets does more damage than a comfortable one every third day.
• Effort. Are you pushing? Bearing down? Holding your breath? That’s the pressure event.
• Completeness. If you finish and it doesn’t feel finished, you go back. Two or three attempts a day is two or three pressure sessions.
• Time. Prolonged sitting is associated with symptomatic hemorrhoids on its own, separate from what you’re doing while you sit (AGA).
• The opposite problem entirely. At a higher tirzepatide dose, diarrhea (23%) was reported roughly twice as often as constipation (11%). You may be going more than usual, with irritation coming from frequency and wiping rather than straining.

Old hemorrhoids wake up

If you’ve had hemorrhoids before — pregnancy, an old injury, years of heavy lifting — that tissue doesn’t reset. A GLP-1 doesn’t have to create anything new. It only has to change your bowel pattern enough to aggravate what’s already there. That’s why one person flares in week two and another never does on an identical dose. It isn’t that the drug is harsher on you. It’s what your anatomy was already carrying.

What to do in the first 48 hours

Answer in brief

Conservative first-line care for hemorrhoid symptoms includes increasing dietary fiber and fluid intake, using a sitz bath for symptom relief, reducing straining and toilet sitting time, and using a topical barrier ointment for irritated skin. These measures address the same contributors that GLP-1 medications can trigger: hard stool, straining, and moisture irritation.

• Increase fiber gradually — at least 25–35 g/day is the target most guidelines cite. Increase it slowly with water to avoid gas and bloating.
• Keep fluids appropriate for your health conditions — less intake from nausea or vomiting makes stool harder. Get your fluid target from your clinician if you have kidney, heart, or fluid-restriction issues.
• Sitz baths — warm (not hot) water, 10–15 minutes, two to three times a day and after bowel movements. Reliable symptom relief. Limited evidence but no meaningful downside.
• Reduce friction when you clean — gentle water cleansing or soft unscented material. Pat dry.
• Protect the skin — a barrier ointment keeps moisture off irritated skin. Ask a pharmacist which product suits you, especially if you’re bleeding, pregnant, on a blood thinner, or the skin is broken.
• Move — physical activity supports bowel regularity.

What the guidelines actually recommend — and what they don’t cover

Sources: ASCRS, Management of Hemorrhoids · AGA/ACG chronic constipation guideline, 2023

What not to do

• Don’t cut, puncture, or squeeze a lump. Ever. Infection risk is real.
• Don’t keep straining to “finish.” Come back later.
• Don’t stack remedies. Fiber plus softener plus magnesium plus senna, all at once, is how people go from constipated to urgently the opposite.
• Don’t take a laxative if obstruction is possible. See the Tier 4 signs above.
• Don’t change your GLP-1 dose to fix this. Next section.

What if it’s diarrhea, not constipation?

Answer in brief

Diarrhea is reported more frequently than constipation on several GLP-1 products, including 30% versus 24% for semaglutide 2.4 mg and 23% versus 11% in the tirzepatide 15 mg trial arm. Frequent loose stools can irritate hemorrhoidal tissue through repeated wiping, moisture, and urgency rather than through straining.

If this is you, set aside most of what you’ve read about GLP-1 bowel problems — it was written for the other issue.

What helps:

• Reduce friction. A peri bottle, bidet attachment, or quick rinse. Repeated dry wiping on inflamed tissue is a major contributor.
• Pat dry, and let the area air out for a moment if you can.
• Barrier ointment before the skin gets raw, not after.
• Change damp clothing promptly.
• Ask before changing anything about your dosing. If you’re wondering whether the timing of your injection is making the worst days land badly, that’s a question for your prescriber — not a solo experiment.

When diarrhea stops being routine: blood mixed through the stool, black stool, fever, severe belly pain, mucus or pus, real dizziness, or not being able to keep fluids down. Any of those and you’re back in the triage table, not in this section.

Should you stop your GLP-1 because of hemorrhoids?

Answer in brief

Decisions to stop, delay, or change a GLP-1 medication should be made by the prescribing clinician rather than independently. Because label data indicate gastrointestinal reactions are most frequently reported during dose escalation, the timing of symptoms relative to a recent dose increase is useful information for a prescriber.

Don’t stop, delay, restart, or change your dose on your own. Whether treatment continues depends on what’s actually causing the symptoms and how severe they are — and hemorrhoid-like symptoms can sit alongside dehydration, obstruction, or something else that changes the answer entirely.

We understand the fear underneath the question. You’ve finally got something working. The scale is moving for the first time in years. And part of you is braced to be told you have to give it back. That’s usually not what happens — and it’s worth knowing why, because stopping isn’t the only lever available.

What your prescriber can actually do

• Adjust the titration. Wegovy’s label says to consider delaying dosage escalation when a dose isn’t tolerated. How long, and on what schedule, is the prescriber’s call.
• Reconsider the maintenance dose. A lower maintenance dose is a recognized option when a higher one isn’t tolerated.
• Put you on a real bowel regimen matched to your actual pattern.
• Look at everything else you take. Plenty of common medications contribute to constipation. Sometimes the GLP-1 is the last straw rather than the whole load.
• Refer you. Persistent bleeding, or a fissure that isn’t healing, may need in-person evaluation and referral to gastroenterology or colorectal surgery.

What to say to your prescriber (copy this)

Answer in brief

A useful message about GLP-1-related anorectal symptoms includes the medication and formulation, current dose, date of the most recent dose increase, change in stool pattern, color and amount of any blood, character and timing of pain, whether a lump is present, whether gas is passing, and any anticoagulant use.

Fill in the brackets. Send it.

Five questions worth asking while you have them

1. Should this be looked at, or can we manage it by message?
2. Could this be a fissure rather than a hemorrhoid? Ask directly — the treatments differ.
3. Given my other medications and history, what should I use to keep stool soft?
4. Should we adjust the timing of my next dose increase?
5. What specifically would make you want me to come in urgently? That last one is the question people forget, and it’s the one that lets you stop checking at midnight.

Tracking the pattern after a dose change

Answer in brief

Gastrointestinal reactions to GLP-1 medications are reported most frequently during dose escalation, but current labels do not define a day-by-day symptom schedule. Recording the dose date alongside stool consistency, straining, bleeding, pain, and hydration from the dose change forward produces a pattern a clinician can evaluate.

You’ll find pages online that lay out exactly which days after your injection you’re at risk. We’re not going to do that, because no label or study establishes it — and inventing a schedule on a page about rectal bleeding is precisely the kind of confident-sounding guess that gets people hurt. What the labels do support is narrower and still useful: the period around a dose increase is when GI reactions cluster.

What to record, starting the day of the dose change

Medication and formulation · dose and dose-change date · stool consistency · frequency · straining · toilet time · blood color and amount · pain pattern · any lump · vomiting · abdominal swelling · whether gas is passing · what you took for it · any clinician contact.

Two or three cycles of that and you’ll have something better than a memory. You’ll see whether your hard stools land three days after the increase or eight, whether they’re getting worse each step or settling, and whether what you’re taking is helping.

Five habits that do the heavy lifting

1. Watch consistency, not frequency. If it’s getting harder, act that day.
2. Go when you get the urge rather than holding it.
3. Limit toilet time. If nothing’s happening, get up.
4. Keep fluids appropriate to your own health conditions, especially if intake is down or you’ve had vomiting or diarrhea.
5. Ask before the increase, not after. At your next appointment, ask what to do if constipation shows up — so you’re not improvising at 11 p.m.

What a clinician will actually do

Answer in brief

Evaluation of anorectal bleeding typically begins with a symptom history and external examination, and may include a digital rectal examination or anoscopy. Depending on age, bleeding pattern, and risk factors, a clinician may recommend sigmoidoscopy or colonoscopy. Office-based treatments for internal hemorrhoids include rubber band ligation, sclerotherapy, infrared coagulation, and electrocoagulation.

Let’s take the mystery out of this, because avoidance is the real risk here and embarrassment is what drives it.

• The history. Most of the visit. What the blood looks like, when it hurts, what your stool has been doing, what you take. If you bring your dose dates, you’re already ahead of most patients.
• A look. External inspection.
• A digital rectal examination. A gloved, lubricated finger. This may be uncomfortable, and it can be genuinely painful if you have a fissure, a thrombosis, or an abscess — tell the clinician if the pain is severe, because that itself is information.
• Anoscopy, sometimes. A short lubricated scope used to examine the anal canal and lower rectum. It’s how internal hemorrhoids and fissures actually get identified, since a finger can miss them.
• Further testing, sometimes. Depending on your age, risk factors, and what the bleeding is doing, they may recommend sigmoidoscopy or colonoscopy. That isn’t a sign they think you have cancer. It’s a sign they’re doing the job properly.

If it is a hemorrhoid, treatment escalates in steps. Many are managed conservatively at first. If that doesn’t work, NIDDK describes office procedures for internal hemorrhoids — rubber band ligation, sclerotherapy, infrared coagulation, electrocoagulation — with surgery reserved for larger or unresponsive cases (NIDDK).

If it’s a fissure, treatment is different. Which is exactly why guessing costs you months.

If your program has no one to call

Answer in brief

GLP-1 telehealth programs differ in how quickly a patient can reach a clinician about a side effect. Access to clinical support does not substitute for in-person evaluation of rectal bleeding.

A lot of people reading this page aren’t going to call anyone — not because they don’t want to, but because they don’t know who to call or how long it’ll take. That’s not a failure on your part. But it’s a gap worth closing before your next dose increase.

Four questions that tell you what your program is actually worth

1. Who answers your messages — a licensed clinician, or a support team who routes to one?
2. Does the program publish a response-time standard? Many don’t. “No published standard” is itself an answer.
3. What happens after hours and on weekends?
4. Does a dose adjustment require a new consultation fee? Given that escalation is when problems cluster, this is the one that bites.

Neither of these is the answer to bleeding. That needs an exam. Both are answers to “I have nobody to ask about my dose next month.” Not sure which route fits? The quiz at the bottom of this page sorts it in about a minute.

Questions people ask about GLP-1 hemorrhoids

Answer in brief

Medication-specific answers differ because current labels cover different formulations, doses, populations, and reporting methods. The consistent findings are that bowel changes can contribute to hemorrhoid symptoms indirectly, that no label in our index supplies a numeric hemorrhoid incidence, and that new rectal bleeding should be evaluated rather than self-diagnosed.

Does Ozempic cause hemorrhoids?

Ozempic's label doesn't list hemorrhoids. It does report constipation (5.0% at 0.5 mg, 3.1% at 1 mg vs 1.5% placebo) and diarrhea (8.5% and 8.8% vs 1.9%), both of which can contribute indirectly. Those rates come from type 2 diabetes trials at lower doses than weight-management dosing, so they don't describe every Ozempic user's experience.

Does Wegovy cause hemorrhoids?

Wegovy's label names hemorrhoids among reactions occurring more often than placebo in adults treated with the injection, and says these were most frequently reported during dose escalation. No percentage is given. Being named on a label is not proof of direct causation, and the head-to-head data suggests it doesn't mean Wegovy is harder on hemorrhoids than tirzepatide.

Does Zepbound or Mounjaro cause hemorrhoids?

Neither label lists hemorrhoids. Both report constipation and diarrhea. In the Zepbound trial arms, diarrhea (19–23%) was reported more often than constipation (11–17%), and the gap was widest in the highest-dose arm.

Which GLP-1 is least likely to cause hemorrhoids?

No published evidence answers this. Label rates come from non-comparable trials, and the one head-to-head comparison found constipation rates 1.5 percentage points apart. Don’t use label percentages as a reason to switch — but do raise persistent side effects with your prescriber, who has better levers than a medication swap.

Is rectal bleeding on a GLP-1 an emergency?

Usually not. A small amount of bright red blood without severe pain is the most commonly reported pattern. But heavy or continuous bleeding, black or tarry stool, blood mixed through the stool, severe abdominal pain, fever, or faintness need emergency care — and all new bleeding should be evaluated, because color and volume don’t identify the source.

How long does a hemorrhoid flare last?

It depends on what it is. Mild flares often improve within about a week of conservative care. A thrombosed external hemorrhoid managed without surgery typically takes longer, and reported recovery times vary widely between individuals. NIDDK advises following up if over-the-counter treatment hasn’t helped after about a week.

Can I use Preparation H or hydrocortisone cream with a GLP-1?

There's no known interaction between topical hemorrhoid products and GLP-1 medications, but follow the product's directions and don't use them long-term unsupervised. Ask a pharmacist if you're bleeding, pregnant, on a blood thinner, or the skin is broken.

Can I take MiraLAX or a stool softener with my GLP-1?

Often yes — PEG 3350 carries the strongest guideline recommendation among over-the-counter options for chronic constipation. But the right choice depends on whether you’re actually constipated or having diarrhea, your kidney function, and your other medications. Confirm with your prescriber or pharmacist.

Why do I have hemorrhoids if I’m not constipated?

Frequency isn’t the measure. Daily but hard stools, straining, incomplete emptying, and long toilet sits all contribute. So does frequent diarrhea, through irritation rather than pressure.

Is black stool a hemorrhoid symptom?

No. Black or tarry stool suggests bleeding higher in the digestive tract and needs urgent evaluation. Iron supplements and bismuth products can also darken stool — mention them, but get checked either way.

Do the label rates apply to compounded semaglutide or tirzepatide?

No. Label adverse-event rates describe the FDA-approved products studied in those trials. Compounded semaglutide and tirzepatide are different products that have not been reviewed by the FDA for safety, effectiveness, or quality — those numbers do not transfer.

I don’t have a regular doctor. Who should I call?

Primary care can evaluate most anorectal symptoms and will refer if needed. Persistent bleeding, or a fissure that isn’t healing, may warrant referral to gastroenterology or colorectal surgery. Start with whoever you can see soonest.

How we verified this page

Answer in brief

This page is based primarily on current FDA prescribing information, supplemented by clinical guidance from gastroenterology and colorectal surgery organizations. Adverse-reaction rates were read from label text rather than secondary summaries.

• Opened current FDA prescribing information for Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda; searched each adverse-reaction section for the exact term hemorrhoid
• Recorded constipation and diarrhea rates alongside formulation, dose, indication, and trial population
• Pulled SURMOUNT-5 adverse-event data to compare reported constipation and diarrhea under a single protocol. That trial did not measure hemorrhoid incidence and does not explain the label-wording difference
• Checked hemorrhoid treatment and thrombosis guidance against ASCRS and NIDDK; constipation treatment against the 2023 AGA/ACG guideline — keeping the two separate, because they answer different questions
• Checked colorectal cancer red-flag data against JNCI (2023) and JAMA Network Open (2024)
• Traced the widely-repeated “41% increase” claim to its origin and found it wasn’t research
• Verified provider pricing and program language on each company’s own current pages

What this page can’t do: diagnose the cause of your bleeding, calculate your personal risk, name a safest medication, or decide whether you should take your next dose.

No clinician reviewed this version, so no medical-review credit is shown. Everything here is sourced to primary documents you can open yourself, and we’d rather you check us than take our word for it.

Corrections. Found an error in a label figure, a broken source link, or an out-of-date price? Tell us at our corrections page and we’ll fix it and note what changed and when.

Sources

• Wegovy (semaglutide) prescribing information — DailyMed
• Zepbound (tirzepatide) prescribing information — DailyMed
• Ozempic (semaglutide) prescribing information — DailyMed
• ASCRS Clinical Practice Guidelines — Management of Hemorrhoids (2024)
• AGA/ACG Clinical Guidelines — Pharmacological Management of Chronic Idiopathic Constipation (2023)
• NIDDK — Hemorrhoids treatment
• NIDDK — GI bleeding symptoms and causes
• Holowatyj AN et al. — Warning signs of colorectal cancer in young adults, JNCI, 2023
• Meta-analysis of early-onset colorectal cancer presenting symptoms, JAMA Network Open, 2024
• Lilly — Zepbound SURMOUNT-5 clinical data
• Mayo Clinic — Anal Fissure: Symptoms and causes
• AGA Patient Center — Hemorrhoids